A detailed history of Captrust Financial Advisors transactions in Abb Vie Inc. stock. As of the latest transaction made, Captrust Financial Advisors holds 1,228,865 shares of ABBV stock, worth $206 Million. This represents 0.74% of its overall portfolio holdings.

Number of Shares
1,228,865
Previous 1,167,761 5.23%
Holding current value
$206 Million
Previous $200 Million 21.16%
% of portfolio
0.74%
Previous 0.65%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$163.84 - $199.33 $10 Million - $12.2 Million
61,104 Added 5.23%
1,228,865 $243 Million
Q2 2024

Aug 14, 2024

BUY
$154.79 - $180.76 $37.4 Million - $43.6 Million
241,477 Added 26.07%
1,167,761 $200 Million
Q1 2024

May 15, 2024

SELL
$159.82 - $182.1 $5.61 Million - $6.39 Million
-35,080 Reduced 3.65%
926,284 $169 Million
Q4 2023

Feb 14, 2024

BUY
$137.6 - $154.97 $15.3 Million - $17.2 Million
110,849 Added 13.03%
961,364 $149 Million
Q3 2023

Nov 14, 2023

BUY
$133.59 - $154.65 $5.76 Million - $6.67 Million
43,111 Added 5.34%
850,515 $127 Million
Q2 2023

Aug 14, 2023

BUY
$132.51 - $164.9 $8.52 Million - $10.6 Million
64,273 Added 8.65%
807,404 $109 Million
Q1 2023

May 15, 2023

BUY
$144.61 - $166.54 $6.83 Million - $7.86 Million
47,205 Added 6.78%
743,131 $118 Million
Q4 2022

Feb 15, 2023

BUY
$138.31 - $165.87 $4.74 Million - $5.69 Million
34,285 Added 5.18%
695,926 $113 Million
Q3 2022

Nov 16, 2022

BUY
$134.21 - $153.93 $13.2 Million - $15.1 Million
98,200 Added 17.43%
661,641 $88.8 Million
Q2 2022

Aug 23, 2022

SELL
$137.62 - $174.96 $4.05 Million - $5.14 Million
-29,396 Reduced 4.96%
563,441 $86.3 Million
Q2 2022

Aug 16, 2022

BUY
$137.62 - $174.96 $14.1 Million - $17.9 Million
102,198 Added 20.83%
592,837 $90.8 Million
Q1 2022

May 16, 2022

BUY
$131.98 - $163.75 $4.3 Million - $5.34 Million
32,588 Added 7.11%
490,639 $79.5 Million
Q4 2021

Feb 14, 2022

BUY
$107.43 - $135.93 $5.52 Million - $6.98 Million
51,338 Added 12.62%
458,051 $62 Million
Q3 2021

Nov 16, 2021

BUY
$106.4 - $120.78 $7.08 Million - $8.04 Million
66,561 Added 19.57%
406,713 $43.9 Million
Q2 2021

Aug 16, 2021

BUY
$105.21 - $117.21 $1.95 Million - $2.17 Million
18,536 Added 5.76%
340,152 $38.3 Million
Q1 2021

May 17, 2021

BUY
$102.3 - $112.62 $3.61 Million - $3.98 Million
35,298 Added 12.33%
321,616 $34.8 Million
Q4 2020

Feb 16, 2021

BUY
$80.49 - $108.67 $1.33 Million - $1.8 Million
16,559 Added 6.14%
286,318 $30.7 Million
Q3 2020

Nov 17, 2020

SELL
$85.91 - $100.83 $664,771 - $780,222
-7,738 Reduced 2.79%
269,759 $23.5 Million
Q2 2020

Aug 14, 2020

BUY
$73.37 - $98.18 $2.51 Million - $3.36 Million
34,236 Added 14.07%
277,497 $27.5 Million
Q1 2020

May 15, 2020

BUY
$64.5 - $97.79 $5.16 Million - $7.83 Million
80,026 Added 49.03%
243,261 $17.9 Million
Q4 2019

Feb 14, 2020

BUY
$72.13 - $90.25 $7.42 Million - $9.28 Million
102,827 Added 170.22%
163,235 $14.6 Million
Q3 2019

Nov 14, 2019

BUY
$62.98 - $75.72 $109,144 - $131,222
1,733 Added 2.95%
60,408 $4.57 Million
Q2 2019

Aug 13, 2019

SELL
$65.7 - $83.98 $27,265 - $34,851
-415 Reduced 0.7%
58,675 $4.27 Million
Q1 2019

May 15, 2019

SELL
$77.14 - $90.79 $3.38 Million - $3.98 Million
-43,870 Reduced 42.61%
59,090 $4.76 Million
Q4 2018

Feb 13, 2019

BUY
$77.85 - $96.01 $111,559 - $137,582
1,433 Added 1.41%
102,960 $9.49 Million
Q3 2018

Nov 15, 2018

BUY
$88.91 - $98.84 $181,998 - $202,325
2,047 Added 2.06%
101,527 $9.6 Million
Q2 2018

Aug 13, 2018

BUY
$89.78 - $106.23 $1.74 Million - $2.06 Million
19,371 Added 24.18%
99,480 $9.22 Million
Q1 2018

May 15, 2018

SELL
$92.01 - $123.21 $1.18 Million - $1.59 Million
-12,873 Reduced 13.84%
80,109 $7.33 Million
Q4 2017

Feb 14, 2018

BUY
$89.56 - $98.21 $8.09 Million - $8.88 Million
90,371 Added 3461.16%
92,982 $8.99 Million
Q3 2017

Feb 16, 2018

BUY
$69.85 - $89.22 $182,378 - $232,953
2,611
2,611 $292,000

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $297B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track Captrust Financial Advisors Portfolio

Follow Captrust Financial Advisors and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Captrust Financial Advisors, based on Form 13F filings with the SEC.

News

Stay updated on Captrust Financial Advisors with notifications on news.